304 related articles for article (PubMed ID: 20709233)
21. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.
Cahill K; Ussher M
Cochrane Database Syst Rev; 2007 Oct; (4):CD005353. PubMed ID: 17943852
[TBL] [Abstract][Full Text] [Related]
22. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.
Cahill K; Ussher M
Cochrane Database Syst Rev; 2007 Jul; (3):CD005353. PubMed ID: 17636794
[TBL] [Abstract][Full Text] [Related]
23. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
Boekholdt SM; Jukema JW; Peters RJ
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
[TBL] [Abstract][Full Text] [Related]
24. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Scheen AJ
J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
[TBL] [Abstract][Full Text] [Related]
25. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial.
Soyka M; Koller G; Schmidt P; Lesch OM; Leweke M; Fehr C; Gann H; Mann KF;
J Clin Psychopharmacol; 2008 Jun; 28(3):317-24. PubMed ID: 18480689
[TBL] [Abstract][Full Text] [Related]
26. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
[TBL] [Abstract][Full Text] [Related]
27. Does rimonabant independently affect free fatty acid and glucose metabolism?
Triay J; Mundi M; Klein S; Toledo FG; Smith SR; Abu-Lebdeh H; Jensen M
J Clin Endocrinol Metab; 2012 Mar; 97(3):819-27. PubMed ID: 22170727
[TBL] [Abstract][Full Text] [Related]
28. Rimonabant: obituary for a wonder drug.
Boekholdt SM; Peters RJ
Lancet; 2010 Aug; 376(9740):489-90. PubMed ID: 20709215
[No Abstract] [Full Text] [Related]
29. Reasons for and time to discontinuation of rimonabant therapy: a modified prescription-event monitoring study.
Willemen MJ; Mantel-Teeuwisse AK; Buggy Y; Layton D; Straus SM; Leufkens HG; Egberts TC
Drug Saf; 2012 Dec; 35(12):1147-58. PubMed ID: 23061737
[TBL] [Abstract][Full Text] [Related]
30. Rimonabant.
Henness S; Robinson DM; Lyseng-Williamson KA
Drugs; 2006; 66(16):2109-19; discussion 2120-1. PubMed ID: 17112304
[TBL] [Abstract][Full Text] [Related]
31. Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome.
Motaghedi R; Lipman EG; Hogg JE; Christos PJ; Vogiatzi MG; Angulo MA
Eur J Med Genet; 2011; 54(1):14-8. PubMed ID: 20965292
[TBL] [Abstract][Full Text] [Related]
32. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
33. Rimonabant for the treatment of obesity.
Samat A; Tomlinson B; Taheri S; Thomas GN
Recent Pat Cardiovasc Drug Discov; 2008 Nov; 3(3):187-93. PubMed ID: 18991793
[TBL] [Abstract][Full Text] [Related]
34. Long-term effects of weight-reducing drugs in people with hypertension.
Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
[TBL] [Abstract][Full Text] [Related]
35. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
[TBL] [Abstract][Full Text] [Related]
36. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E
Lancet Oncol; 2019 Sep; 20(9):1226-1238. PubMed ID: 31402321
[TBL] [Abstract][Full Text] [Related]
38. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ray KK; Colhoun HM; Szarek M; Baccara-Dinet M; Bhatt DL; Bittner VA; Budaj AJ; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Loizeau V; Lopes RD; Moryusef A; Murin J; Pordy R; Ristic AD; Roe MT; Tuñón J; White HD; Zeiher AM; Schwartz GG; Steg PG;
Lancet Diabetes Endocrinol; 2019 Aug; 7(8):618-628. PubMed ID: 31272931
[TBL] [Abstract][Full Text] [Related]
39. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial.
Tardif JC; McMurray JJ; Klug E; Small R; Schumi J; Choi J; Cooper J; Scott R; Lewis EF; L'Allier PL; Pfeffer MA;
Lancet; 2008 May; 371(9626):1761-8. PubMed ID: 18502300
[TBL] [Abstract][Full Text] [Related]
40. Rimonabant: new drug. Obesity: loss of a few kilos, many questions.
Prescrire Int; 2006 Aug; 15(84):123-6. PubMed ID: 16977739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]